Sales StrategySales Strategy for a Big Jumpfor a Big Jump
Kenichi YanagisawaBoard DirectorSenior Managing Executive OfficerDivision Manager of Sales & Marketing Division
Mitsubishi Tanabe Pharma Corporation
May 10, 2012
1
FY2011 FY2012 FY2015
Sales Contribution of Remicade and New Products
Remicadeand
New Products
Remicadeand
New Products
21％
21％
28％
28％
RemicadeSimponiLexaproTelavicImuseraMP-513
To Further Expansion
2
Most Priority Products: Remicade and Simponi
apidapidemicadeemicade
iimplempleimponiimponi
Sales
20
40
60
80
2002 2004 2006 2008 2010 2012
100(Bil. JPY)
Remicade & SimponiRemicade & SimponiRemicade
For 10 years after the launch, it has been used for more than 50,000 patients with RA and for more than 80,000 cumulated patients with all approved indications. Reducing the burden of patients and medical professionals by shortening
infusion time. Contributing to medical services by Remicade (i.v.) and Simponi (s.c.).
Making foundation of 100 bil. JPY sales
3
This new option of shortening infusion time is expected to offer greater convenience for both patients and medical settings.
This new option of shortening infusion time is expected to offer greater convenience for both patients and medical settings.
A New Option to Shorten Infusion Time of Remicade
Dose schedule
60 min
Infusion time
60 min
60 min 60 min
2 hours
1 hour
Infusion time can be shortened without exceeding 5mg/kg/hour.
No infusion reaction
0wk
2wk
6wk
14wk
22wk
30wk
Intr
oduc
tion
trea
tmen
tM
aint
enan
cetr
eatm
ent
4
Key Product: Lexapro
LexaproLexapro
4月 5月 6月 7月 8月
The large prescription rise
by long term prescription
Apr. May Jun. Jul. Aug.
Lifting a ban on long-term prescription in August, 2012 Enhancing actions in psychiatry field
- Renewing co-promotion scheme with Mochida Pharmaceutical- Enhancing cooperation with Yoshitomiyakuhin, our subsidiary,
which has strength in psychiatry area
AggressiveactivitiesPreparation for
long-term prescription
5
Enhancing Co-promotion
MochidaPharmaceutical
MochidaPharmaceutical
Yoshitomi-yakuhin
Yoshitomi-yakuhin
Mitsubishi TanabePharma CorporationMitsubishi Tanabe
Pharma Corporation
Co-promotionTriple visits in psychiatry area
6
Key Products: Anti-diabetic drugs
MP-513 & TA-7284MP-513 & TA-7284
MP-513Teneligliptin
MP-513Teneligliptin
TA-7284Canagliflozin
TA-7284Canagliflozin
SGLT2 inhibitor
Plan to file in 2013
Strategic alliance with Daiichi Sankyo Promoting usages by new style of joint sales activities at
the unprecedented speed Contributing to total care management of metabolism and
CV diseases by the launch of anti-diabetic drugs
DPP4 inhibitor
Filed in Aug 2011
HeartHeartKidneyKidney
DiabetesDiabetesmellitusmellitus
PeripheralPeripheralvesselvessel
7
Strategic Alliance with Daiichi Sankyo
Joint policy ofMR activities
Joint policy ofMR activities
Joint policy of product development
Joint policy of product development
Clinic/Hospital
Promoted by a total of 4,000 MRs
Daiichi SankyoMitsubishi TanabePharma Corporatin
Joint policy ofbusiness operation
Joint policy ofbusiness operation
8
Safety-prioritized Product: Telavic
TelavicTelavic
Number of contracted institutions
Number of patient registrations
708 3,340
NS3-4A protease (enzyme essential for replication of hepatitis C virus) inhibitor Launched on Nov. 28, 2011 Implementing all-patient PMS (n=3,000)
Launch End of Apr.
Cum
ulat
ive
patie
nt re
gist
ratio
ns
3000
2000
1000
4000
9
Safety-prioritized product: Imusera
ImuseraImusera
“Japanese origin, World’s first” S1P1 receptor functional antagonist Launched on Nov. 28, 2011 (Co-marketing with Novartis Pharma) Implementing all-patient PMS (n=1,000 for two companies)
End of Apr.Jan. 22
Number of contracted institutions, MTPC only
Number of patient registrations, MTPC only
189 237
Two-company sum totalC
umul
ativ
e pa
tient
regi
stra
tions
by M
TPC
and
Nov
artis
pha
rma
0
100
200
300
400
500
600
N=537
10
We contribute toParadigm Shift of treatment.
11
We overcome competitionand make a “Big Jump”.We overcome competitionand make a “Big Jump”.
12
12
Cautionary Statement
The statements contained in this presentation is based on a numberof assumptions and belief in light of the information currently availableto management of the company and is subject to significantrisks and uncertainties.
